Targeted imaging and therapy of brain cancer using theranostic nanoparticles

Molecular Pharmaceutics

Volumn 7, Issue 6, 2010, Pages 1921-1929

  Bhojani, Mahaveer Swaroop ^a   Van Dort, Marcian ^a,b   Rehemtulla, Alnawaz ^a   Ross, Brian D ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; DOXORUBICIN; MACROGOL; NANOPARTICLE; PACLITAXEL; POLYACRYLAMIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ARTICLE; BRAIN CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RESEARCH; HUMAN; HYDROPHILICITY; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

ANIMALS; BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; HUMANS; NANOPARTICLES;

EID: 78649924497     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100298r     Document Type: Article

References (84)

1. http://www.cancer.gov/statistics.
2. http://www.cancer.gov/cancertopics/types/brain.
3. Packer, R. J.; MacDonald, T.; Vezina, G. Central nervous system tumors Hematol. Oncol. Clin. North Am. 2010, 24 (1) 87-108
4. Fujimaki, T. Central nervous system germ cell tumors: classification, clinical features, and treatment with a historical overview J. Child Neurol. 2009, 24 (11) 1439-45
5. Huse, J. T.; Holland, E. C. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma Nat. Rev. Cancer 2010, 10 (5) 319-31
6. Hsu, C. C.; Pai, C. Y.; Kao, H. W.; Hsueh, C. J.; Hsu, W. L.; Lo, C. P. Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J.Clin. Neurosci. 2010, 17 (5) 584-7
7. Wintermark, M.; Sincic, R.; Sridhar, D.; Chien, J. D. Cerebral perfusion CT: technique and clinical applications J. Neuroradiol. 2008, 35 (5) 253-60
8. Tovi, M. MR imaging in cerebral gliomas analysis of tumour tissue components Acta Radiol. Suppl. 1993, 384, 1-24
9. Hanson, M. W.; Glantz, M. J.; Hoffman, J. M.; Friedman, A. H.; Burger, P. C.; Schold, S. C.; Coleman, R. E. FDG-PET in the selection of brain lesions for biopsy J. Comput. Assist. Tomogr. 1991, 15 (5) 796-801
10. Pichler, A.; Prior, J. L.; Piwnica-Worms, D. Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (6) 1702-7
11. Boekelheide, K.; Lee, J.; Shipp, E. B.; Richburg, J. H.; Li, G. Expression of Fas system-related genes in the testis during development and after toxicant exposure Toxicol. Lett. 1998, 102-103, 503-8
12. Shamji, M. F.; Fric-Shamji, E. C.; Benoit, B. G. Brain tumors and epilepsy: pathophysiology of peritumoral changes Neurosurg. Rev. 2009, 32 (3) 275-84, discussion 284-6
13. Lehmann, P.; Vallee, J. N.; Saliou, G.; Monet, P.; Bruniau, A.; Fichten, A.; De Marco, G. Dynamic contrast-enhanced T2*-weighted MR imaging: a peritumoral brain oedema study J. Neuroradiol. 2009, 36 (2) 88-92
14. Pronin, I. N.; McManus, K. A.; Holodny, A. I.; Peck, K. K.; Kornienko, V. N. Quantification of dispersion of Gd-DTPA from the initial area of enhancement into the peritumoral zone of edema in brain tumors J. Neurooncol. 2009, 94 (3) 399-408
15. Schoenegger, K.; Oberndorfer, S.; Wuschitz, B.; Struhal, W.; Hainfellner, J.; Prayer, D.; Heinzl, H.; Lahrmann, H.; Marosi, C.; Grisold, W. Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma Eur. J. Neurol. 2009, 16 (7) 874-8
16. Koo, Y. E.; Reddy, G. R.; Bhojani, M.; Schneider, R.; Philbert, M. A.; Rehemtulla, A.; Ross, B. D.; Kopelman, R. Brain cancer diagnosis and therapy with nanoplatforms Adv. Drug Delivery Rev. 2006, 58 (14) 1556-77
17. Rutka, J. T.; Kuo, J. S. Pediatric surgical neuro-oncology: current best care practices and strategies J. Neurooncol. 2004, 69 (1-3) 139-50
18. Young, R. J.; Brennan, N.; Fraser, J. F.; Brennan, C. Advanced imaging in brain tumor surgery Neuroimaging Clin. North Am. 2010, 20 (3) 311-35
19. Gupta, A.; Shah, A.; Young, R. J.; Holodny, A. I. Imaging of brain tumors: functional magnetic resonance imaging and diffusion tensor imaging Neuroimaging Clin. North Am. 2010, 20 (3) 379-400
20. Armstrong, C. L.; Hunter, J. V.; Ledakis, G. E.; Cohen, B.; Tallent, E. M.; Goldstein, B. H.; Tochner, Z.; Lustig, R.; Judy, K. D.; Pruitt, A.; Mollman, J. E.; Stanczak, E. M.; Jo, M. Y.; Than, T. L.; Phillips, P. Late cognitive and radiographic changes related to radiotherapy: initial prospective findings Neurology 2002, 59 (1) 40-8
21. Pollack, I. F.; Claassen, D.; al-Shboul, Q.; Janosky, J. E.; Deutsch, M. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases J. Neurosurg. 1995, 82 (4) 536-47
22. Belda-Iniesta, C.; de Castro Carpeno, J.; Casado Saenz, E.; Cejas Guerrero, P.; Perona, R.; Gonzalez Baron, M. Molecular biology of malignant gliomas Clin. Transl. Oncol. 2006, 8 (9) 635-41
23. Bhojani, M. S.; Reddy, G. R.; Koo, Y.; Philbert, M.; Kopelman, R.; Rehemtulla, A.; Ross, B. D. Multifunctional nanoparticles for targeted imaging and therapy. In Cancer Nanotechnology; Nalwa, H. S.; Wester, T. J., Eds.; American Scientific Publishers: 2007; pp 81 - 9.
24. Bhojani, M. S.; Laxman, B.; Ross, B. D.; Rehemtulla, A. Molecular Imaging in Cancer. In Apoptosis and Cancer Therapy; Debatin, K.-M., Fluda, S., Eds.; Wiley-VCH: Weinheim, 2006; Vol. II, pp 37 - 59.
25. http://nano.cancer.gov.
26. Kopelman, R.; Philbert, M.; Koo, Y.-E. L.; Moffat, B. A.; Reddy, G. R.; McConville, P.; Hall, D. E.; Chenevert, T. L.; Bhojani, M. S.; Buck, S. M.; Rehemtulla, A.; Ross, B. D. Multifunctional Nanoparticle Platforms for In Vivo MRI Enhancement and Photodynamic Therapy of a Rat Brain Cancer J. Magn. Magn. Mater. 2005, 293, 404-410
27. Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Nanomedicine: current status and future prospects FASEB J. 2005, 19 (3) 311-30
28. Mross, K.; Niemann, B.; Massing, U.; Drevs, J.; Unger, C.; Bhamra, R.; Swenson, C. E. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study Cancer Chemother. Pharmacol. 2004, 54 (6) 514-24
29. Kukowska-Latallo, J. F.; Candido, K. A.; Cao, Z.; Nigavekar, S. S.; Majoros, I. J.; Thomas, T. P.; Balogh, L. P.; Khan, M. K.; Baker, J. R., Jr. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer Cancer Res. 2005, 65 (12) 5317-24
30. McNeil, S. E. Nanotechnology for the biologist J. Leukocyte Biol. 2005, 78 (3) 585-94
31. Moffat, B. A.; Reddy, G. R.; McConville, P.; Hall, D. E.; Chenevert, T. L.; Kopelman, R. R.; Philbert, M.; Weissleder, R.; Rehemtulla, A.; Ross, B. D. A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI Mol. Imaging 2003, 2 (4) 324-32
32. Crowder, K. C.; Hughes, M. S.; Marsh, J. N.; Barbieri, A. M.; Fuhrhop, R. W.; Lanza, G. M.; Wickline, S. A. Sonic activation of molecularly-targeted nanoparticles accelerates transmembrane lipid delivery to cancer cells through contact-mediated mechanisms: implications for enhanced local drug delivery Ultrasound Med. Biol. 2005, 31 (12) 1693-700
33. Liong, M.; Lu, J.; Kovochich, M.; Xia, T.; Ruehm, S. G.; Nel, A. E.; Tamanoi, F.; Zink, J. I. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery ACS Nano 2008, 2 (5) 889-96
34. Medarova, Z.; Kumar, M.; Ng, S. W.; Yang, J.; Barteneva, N.; Evgenov, N. V.; Petkova, V.; Moore, A. Multifunctional magnetic nanocarriers for image-tagged SiRNA delivery to intact pancreatic islets Transplantation 2008, 86 (9) 1170-7
35. Kumar, A.; Jena, P. K.; Behera, S.; Lockey, R. F.; Mohapatra, S.; Mohapatra, S. Multifunctional magnetic nanoparticles for targeted delivery Nanomedicine 2010, 6 (1) 64-9
36. McCarthy, J. R.; Weissleder, R. Multifunctional magnetic nanoparticles for targeted imaging and therapy Adv. Drug Delivery Rev. 2008, 60 (11) 1241-51
37. Blanco, E.; Kessinger, C. W.; Sumer, B. D.; Gao, J. Multifunctional micellar nanomedicine for cancer therapy Exp. Biol. Med. (Maywood) 2009, 234 (2) 123-31
38. Guo, R.; Zhang, L.; Qian, H.; Li, R.; Jiang, X.; Liu, B. Multifunctional nanocarriers for cell imaging, drug delivery, and near-IR photothermal therapy Langmuir 26 (8) 5428-34
39. Bhaskar, S.; Tian, F.; Stoeger, T.; Kreyling, W.; de la Fuente, J. M.; Grazu, V.; Borm, P.; Estrada, G.; Ntziachristos, V.; Razansky, D. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging Part. Fibre Toxicol. 2010, 7, 3
40. Gindy, M. E.; Prud'homme, R. K. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy Expert Opin. Drug Delivery 2009, 6 (8) 865-78
41. Masotti, A. Multifuntional nanoparticles: preparation and applications in biomedicine and in non-invasive bioimaging Recent Pat. Nanotechnol. 2010, 4 (1) 53-62
42. Pan, D.; Lanza, G. M.; Wickline, S. A.; Caruthers, S. D. Nanomedicine: perspective and promises with ligand-directed molecular imaging Eur. J. Radiol. 2009, 70 (2) 274-85
43. Chen, W.; Bardhan, R.; Bartels, M.; Perez-Torres, C.; Pautler, R. G.; Halas, N. J.; Joshi, A. A molecularly targeted theranostic probe for ovarian cancer Mol. Cancer Ther. 2010, 9 (4) 1028-38
44. Jain, R. K. Transport of molecules, particles, and cells in solid tumors Annu. Rev. Biomed. Eng. 1999, 1, 241-63
45. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Delivery Rev. 2010. DOI: 10.1016/j.addr.2010.04.009.
46. Greish, K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting Methods Mol. Biol. 2010, 624, 25-37
47. Maeda, H.; Bharate, G. Y.; Daruwalla, J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 2009, 71 (3) 409-19
48. Moghimi, S. M.; Hunter, A. C. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine Trends Biotechnol. 2000, 18 (10) 412-20
49. Park, E. K.; Lee, S. B.; Lee, Y. M. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs Biomaterials 2005, 26 (9) 1053-61
50. Farokhzad, O. C.; Jon, S.; Khademhosseini, A.; Tran, T. N.; Lavan, D. A.; Langer, R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells Cancer Res. 2004, 64 (21) 7668-72
51. Gref, R.; Minamitake, Y.; Peracchia, M. T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres Science 1994, 263 (5153) 1600-3
52. Chari, R. V. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy Adv. Drug Delivery Rev. 1998, 31 (1-2) 89-104
53. Mansour, A. M.; Drevs, J.; Esser, N.; Hamada, F. M.; Badary, O. A.; Unger, C.; Fichtner, I.; Kratz, F. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2 Cancer Res. 2003, 63 (14) 4062-6
54. Guo, X.; Szoka, F. C., Jr. Chemical approaches to triggerable lipid vesicles for drug and gene delivery Acc. Chem. Res. 2003, 36 (5) 335-41
55. Gordon, E. M.; Lopez, F. F.; Cornelio, G. H.; Lorenzo, C. C., 3rd; Levy, J. P.; Reed, R. A.; Liu, L.; Bruckner, H. W.; Hall, F. L. Pathotropic nanoparticles for cancer gene therapy Rexin-GIV: three-year clinical experience Int. J. Oncol. 2006, 29 (5) 1053-64
56. Morse, M. Technology evaluation: Rexin-G, Epeius Biotechnologies Curr. Opin. Mol. Ther. 2005, 7 (2) 164-9
57. Brannon-Peppas, L.; Blanchette, J. O. Nanoparticle and targeted systems for cancer therapy Adv. Drug Delivery Rev. 2004, 56 (11) 1649-59
58. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis Adv. Drug Delivery Rev. 2002, 54 (5) 631-51
59. Folkman, J.; Watson, K.; Ingber, D.; Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia Nature 1989, 339 (6219) 58-61
60. Veiseh, O.; Sun, C.; Gunn, J.; Kohler, N.; Gabikian, P.; Lee, D.; Bhattarai, N.; Ellenbogen, R.; Sze, R.; Hallahan, A.; Olson, J.; Zhang, M. Optical and MRI multifunctional nanoprobe for targeting gliomas Nano Lett. 2005, 5 (6) 1003-8
61. Trehin, R.; Figueiredo, J. L.; Pittet, M. J.; Weissleder, R.; Josephson, L.; Mahmood, U. Fluorescent nanoparticle uptake for brain tumor visualization Neoplasia 2006, 8 (4) 302-11
62. Brooks, P. C.; Montgomery, A. M.; Rosenfeld, M.; Reisfeld, R. A.; Hu, T.; Klier, G.; Cheresh, D. A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 1994, 79 (7) 1157-64
63. Bibby, D. C.; Talmadge, J. E.; Dalal, M. K.; Kurz, S. G.; Chytil, K. M.; Barry, S. E.; Shand, D. G.; Steiert, M. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice Int. J. Pharm. 2005, 293 (1-2) 281-90
64. Chen, X.; Plasencia, C.; Hou, Y.; Neamati, N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery J. Med. Chem. 2005, 48 (4) 1098-106
65. Chen, X.; Sievers, E.; Hou, Y.; Park, R.; Tohme, M.; Bart, R.; Bremner, R.; Bading, J. R.; Conti, P. S. Integrin alpha v beta 3-targeted imaging of lung cancer Neoplasia 2005, 7 (3) 271-9
66. Ajani, J. A.; Kelsen, D. P.; Haller, D.; Hargraves, K.; Healey, D. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma Cancer J. 2000, 6 (2) 78-81
67. Hinman, L. M.; Hamann, P. R.; Wallace, R.; Menendez, A. T.; Durr, F. E.; Upeslacis, J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics Cancer Res. 1993, 53 (14) 3336-42
68. Lutz, R. J.; Whiteman, K. R. Antibody-maytansinoid conjugates for the treatment of myeloma MAbs 2009, 1 (6) 548-51
69. Singh, R.; Erickson, H. K. Antibody-cytotoxic agent conjugates: preparation and characterization Methods Mol. Biol. 2009, 525, 445-67, xiv
70. Sievers, E. L.; Linenberger, M. Mylotarg: antibody-targeted chemotherapy comes of age Curr. Opin. Oncol. 2001, 13 (6) 522-7
71. Park, J. W.; Hong, K.; Kirpotin, D. B.; Meyer, O.; Papahadjopoulos, D.; Benz, C. C. Anti-HER2 immunoliposomes for targeted therapy of human tumors Cancer Lett. 1997, 118 (2) 153-60
72. Park, J. W.; Benz, C. C.; Martin, F. J. Future directions of liposome- and immunoliposome-based cancer therapeutics Semin. Oncol. 2004, 31 (6 Suppl. 13) 196-205
73. Segal, D. M.; Weiner, G. J.; Weiner, L. M. Bispecific antibodies in cancer therapy Curr. Opin. Immunol. 1999, 11 (5) 558-62
74. Hadjipanayis, C. G.; Machaidze, R.; Kaluzova, M.; Wang, L.; Schuette, A. J.; Chen, H.; Wu, X.; Mao, H. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma Cancer Res. 2010, 70 (15) 6303-12
75. Sun, C.; Fang, C.; Stephen, Z.; Veiseh, O.; Hansen, S.; Lee, D.; Ellenbogen, R. G.; Olson, J.; Zhang, M. Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles Nanomedicine (London) 2008, 3 (4) 495-505
76. Sun, C.; Veiseh, O.; Gunn, J.; Fang, C.; Hansen, S.; Lee, D.; Sze, R.; Ellenbogen, R. G.; Olson, J.; Zhang, M. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes Small 2008, 4 (3) 372-9
77. Reddy, G. R.; Bhojani, M. S.; McConville, P.; Moody, J.; Moffat, B. A.; Hall, D. E.; Kim, G.; Koo, Y. E.; Woolliscroft, M. J.; Sugai, J. V.; Johnson, T. D.; Philbert, M. A.; Kopelman, R.; Rehemtulla, A.; Ross, B. D. Vascular targeted nanoparticles for imaging and treatment of brain tumors Clin. Cancer Res. 2006, 12 (22) 6677-86
78. Yan, F.; Xu, H.; Anker, J.; Kopelman, R.; Ross, B.; Rehemtulla, A.; Reddy, R. Synthesis and characterization of silica-embedded iron oxide nanoparticles for magnetic resonance imaging J. Nanosci. Nanotechnol. 2004, 4 (1-2) 72-6
79. Porkka, K.; Laakkonen, P.; Hoffman, J. A.; Bernasconi, M.; Ruoslahti, E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (11) 7444-9
80. Christian, S.; Pilch, J.; Akerman, M. E.; Porkka, K.; Laakkonen, P.; Ruoslahti, E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels J. Cell Biol. 2003, 163 (4) 871-8
81. Akerman, M. E.; Chan, W. C.; Laakkonen, P.; Bhatia, S. N.; Ruoslahti, E. Nanocrystal targeting in vivo Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (20) 12617-21
82. Wickline, S. A.; Mason, R. P.; Cauthers, S. D.; Chen, J.; Winter, P. M.; Hughes, M. S.; Lanza, G. M. Fluorocarbon Agents for Quantitative Multimodal Molecular Imaging and Targeted Therapeutics; Weissleder, R.; Ross, B. D.; Rehemtulla, A.; Gambhir, S., Eds.; PMPH-USA: Shelton, CT, 2010; pp 542 - 73.
83. Hahn, M. A.; Singh, A. K.; Sharma, P.; Brown, S. C.; Moudgil, B. M. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Anal. Bioanal. Chem. 2010. DOI: 10.1007/s00216-010-4207-5.
84. Dobrovolskaia, M. A.; Germolec, D. R.; Weaver, J. L. Evaluation of nanoparticle immunotoxicity Nat. Nanotechnol. 2009, 4 (7) 411-4